中石化(00386.HK)斥11.5億人幣夥控股股東等成立碳科公司
中國石油化工股份(00386.HK)公布,與控股股東中國石化集團等發起設共同出資設立碳科公司,註冊資本為25億元人民幣(下同),其中公司以現金認繳出資11.5億元,佔碳科公司註冊資本46%。
至於控股股東中國石化集團聯繫人南化公司出資8.5億元,佔碳科公司註冊資本34%,公司附屬聯合石化及中石化油服附屬(01033.HK)石工建、中石化煉化(02386.HK)附屬上海工程與南京工程分別出資1.25億元,各佔碳科公司註冊資本的5%。
交易完成後,碳科公司將會成為公司之附屬公司。碳科公司將從事碳核查、碳資產管理、碳減排等服務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.